Year: 2025
Type: article
Abstract: Central nervous system (CNS) relapse in children with acute lymphoblastic leukemia (ALL) remains an obstacle for long-term survival. Though chimeric antigen receptor T-cells (CAR-T) or hematopoietic stem cells transplant (HSCT) therapy was successfully developed, failure occasionally occurs. In this study, a child with TCF3-PBX1 B-ALL who relapsed a second time after CAR-T therapy followed by allo-HSCT was treated with blinatumomab therapy, bone marrow minimal residual disease negativity was confirmed with two weeks’ blinatumomab infusion. Subsequently, parenchymal infiltration improvement was achieved with additional 14 days’ blinatumomab-included targeted therapy. These results suggest that blinatumomab-included therapy is a potential treatment option for central nervous system B-ALL.
Source: Holistic Integrative Oncology
Authors: Shufang Xue, Gaoyuan Sun, Ruoyao Huang, Han Lin, Shan Liu, Lu Chen, Ying Huang, Chengyi Wang, Yongzhi Zheng, Hui Zhang
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Awards: G5299820107, G7425413672
OpenAlex ID: W7101412944